SAB Biotherapeutics (SABS) AI Stock Analysis

• Market Cap: $20.82M
• Dividend Yield: N/A
• Average Volume (3M): 2.92M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.66
• Revenue Growth: -95.87%
• EPS Growth: 35.25%
• Country: US
• Employees: 63
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -1.09
• Shares Outstanding: 10,411,061
• 10 Day Avg. Volume: 108,608
• 30 Day Avg. Volume: 2,916,773
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.82
• Enterprise Value/Revenue: -41.50K
• Enterprise Value/Gross Profit: -5.20
• Enterprise Value/Ebitda: -0.50
• 1Y Price Target: $10.00
• Price Target Upside: 397.51% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 51 Neutral
• Price Target: $2.00 ▼(-0.50% Downside)

SAB Biotherapeutics' overall stock score is primarily impacted by its financial challenges, including declining revenues and negative cash flow. However, the recent private placement provides a positive outlook by securing substantial funding for future operations. Technical indicators suggest mixed momentum, and the valuation remains challenging due to ongoing losses.

Positive Factors

Clinical Development

SAB-142's encouraging Phase 1 safety and efficacy in healthy volunteers sets the stage for Phase 2b looking to modulate type 1 diabetes progression.

Investor Confidence

Participation from strategic investor Sanofi and new noteworthy investors like RA Capital and Blackstone Multi-Asset Investing highlights strong investor confidence.

Regulatory Approval

The Phase 2b SAFEGUARD trial is confirmed by the FDA to serve as a pivotal trial for FDA approval.

Negative Factors

Adverse Events

SAB-142 was generally well tolerated among healthy volunteers, with most adverse events being mild and resolving quickly, and no drug-related serious adverse events reported.

Market Competition

SAB-142 has a potential competitive dosing regimen with 2-3 days dosing versus 12-14 days with teplizumab, which could be advantageous for outpatient settings.

SAB Biotherapeutics Business Overview & Revenue Model

Company Description

SAB Biotherapeutics (SABS) is a clinical-stage biopharmaceutical company leveraging advanced immunotherapy technologies to develop targeted therapies for infectious diseases, immune disorders, and other unmet medical needs. The company specializes in producing fully human polyclonal antibodies using its proprietary DiversitAb platform, which involves genetically engineered cattle to produce large quantities of human antibodies.

How the Company Makes Money

SAB Biotherapeutics generates revenue primarily through research and development collaborations, government contracts, and grants. The company's revenue streams include milestone payments from strategic partnerships and licensing agreements, where they collaborate with pharmaceutical companies and government agencies to develop and commercialize their antibody-based therapies. Additionally, SAB Biotherapeutics may receive revenue from the sale of its therapeutic products once they gain regulatory approval and enter the market.

SAB Biotherapeutics Financial Statement Overview

Summary

SAB Biotherapeutics faces significant financial challenges, highlighted by declining revenues, persistent losses, and cash flow difficulties. Despite a reasonable equity ratio, the high debt-to-equity ratio and negative net profit margins indicate ongoing financial instability.

Income Statement

SAB Biotherapeutics has experienced a significant decline in revenue over recent years, with total revenue falling from $60.88 million in 2021 to just $1.32 million in 2024. The company has maintained negative EBIT and net income, indicating ongoing operational challenges. Margins have remained weak, with a negative net profit margin, reflecting persistent losses.

Balance Sheet

The company's balance sheet shows a relatively high debt-to-equity ratio, indicating a reliance on debt financing. However, the equity ratio remains reasonable, suggesting some level of financial stability. Stockholders' equity has decreased over the years, which could be a concern if this trend continues.

Cash Flow

SAB Biotherapeutics has faced challenges in generating positive operating cash flow, with significant negative free cash flow in recent years. The company has also shown volatility in financing cash flows, suggesting potential difficulties in maintaining liquidity and funding operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-410.00	1.32M	2.24M	23.90M	60.88M	55.24M
Gross Profit	-3.27M	-3.47M	-1.51M	20.61M	59.22M	55.24M
EBITDA	-33.92M	-28.99M	-38.13M	-15.12M	-15.20M	21.14M
Net Income	-37.06M	-34.10M	-42.19M	-18.74M	-17.14M	20.12M
Balance Sheet
Total Assets	30.13M	44.20M	83.94M	50.90M	79.37M	56.54M
Cash, Cash Equivalents and Short-Term Investments	5.71M	20.76M	56.57M	15.05M	33.21M	12.61M
Total Debt	6.42M	4.67M	5.91M	5.93M	8.52M	8.13M
Total Liabilities	18.11M	18.23M	26.64M	19.85M	40.82M	17.53M
Stockholders Equity	12.02M	25.97M	57.30M	31.06M	38.55M	39.01M
Cash Flow
Free Cash Flow	-38.26M	-34.63M	-25.32M	-7.19M	-7.19M	-2.73M
Operating Cash Flow	-38.11M	-34.29M	-25.12M	3.76M	3.76M	10.00M
Investing Cash Flow	18.05M	-11.96M	-152.70K	-10.94M	-10.94M	-12.72M
Financing Cash Flow	-805.00K	-1.17M	66.77M	1.05M	34.12M	8.98M

SAB Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.01
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SABS, the sentiment is Negative. The current price of 2.01 is below the 20-day moving average (MA) of 2.20, below the 50-day MA of 2.17, and below the 200-day MA of 2.36, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 44.54 is Neutral, neither overbought nor oversold. The STOCH value of 26.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SABS.

SAB Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$19.34B	4.28	-1.43%	3.28%	13.32%	-14.38%
BOLT	52 Neutral	$9.18M	―	-81.33%	―	-62.68%	23.94%
SABS	51 Neutral	$20.82M	―	-127.48%	―	-95.87%	35.25%
MRKR	44 Neutral	$14.62M	―	-144.68%	―	44.55%	-17.92%
IMNN	41 Neutral	$15.91M	―	-491.97%	―	―	45.96%
INAB	34 Underperform	$10.35M	―	-165.56%	―	―	58.67%

SAB Biotherapeutics Corporate Events

SAB Biotherapeutics Secures $175M in Private Placement

On July 21, 2025, SAB Biotherapeutics announced an oversubscribed $175 million private placement with participation from strategic investor Sanofi and other institutional investors. The proceeds are intended to fully fund the Phase 2b SAFEGUARD study of SAB-142 in Stage 3 autoimmune T1D and extend the company’s cash runway into mid-2028. The private placement includes the issuance of Series B nonvoting convertible preferred stock and warrants, potentially raising an additional $284 million if exercised in full. This financing is expected to bolster SAB’s position in the biopharmaceutical industry by supporting the development of its novel immunotherapy platform.

SAB Biotherapeutics Holds Annual Stockholders Meeting

On July 17, 2025, SAB Biotherapeutics, Inc. held its Annual Meeting of Stockholders, where approximately 71.38% of the outstanding shares were represented. During the meeting, shareholders elected four Class I directors and ratified the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions are expected to impact the company’s governance and financial oversight positively.